Potential progress for Pancreatic Cancer treatment
/CRI-Sponsored Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Arthur N. Brodsky, Cancer Research Institute Blog
A novel combination of immunotherapy and chemotherapy shows promise as a first-line option in patients with metastatic pancreatic cancer, according to interim results from a Cancer Research Institute-funded clinical trial that are being revealed today at the 2019 Annual Meeting of the American Association for Cancer Research (AACR19) in Atlanta.
This phase Ib trial is the first to emerge from the partnership between the Cancer Research Institute (CRI), the Parker Institute for Cancer Immunotherapy (PICI), and Bristol-Myers Squibb (BMS) that was formed in 2017 in order to accelerate promising immunotherapy to benefit the patients who need them most.
In this study, patients were treated with combinations of four different drugs, including two standard-of-care chemotherapies and two immunotherapies—one that inhibits the PD-1 immune checkpoint (nivolumab, BMS) and an experimental treatment that activates the CD40 pathway (APX005M, Apexigen).
